Hypersensitivity to intravenous iron: Classification, terminology, mechanisms and management

British Journal of Pharmacology

Volumn 172, Issue 21, 2015, Pages 5025-5036

  Szebeni, Janos ^a,b   Fishbane, S ^c   Hedenus, M ^d   Howaldt, S ^e   Locatelli, F ^f   Patni, S ^g   Rampton, D ^h   Weiss, G ⁱ   Folkersen, J ^j  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF MISKOLC   (Hungary)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d SUNDSVALL HOSPITAL   (Sweden)

^e Research Institute for IBD HaFCED GmbH and CoKG   (Germany)

^f A MANZONI HOSPITAL   (Italy)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j Medbusiness   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; INFUSION FLUID; IRON; OXYGEN;

ANAPHYLAXIS; CLINICAL PROTOCOL; COMPLEMENT ACTIVATION; DESENSITIZATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IRON DEFICIENCY ANEMIA; NOMENCLATURE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM; ANEMIA, IRON-DEFICIENCY; CLASSIFICATION; INTRAVENOUS DRUG ADMINISTRATION;

ANEMIA, IRON-DEFICIENCY; DRUG HYPERSENSITIVITY; HUMANS; INFUSIONS, INTRAVENOUS; IRON;

EID: 84945930081     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13268     Document Type: Review

References (86)

1. Adkinson NFJ, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler JD, et al., (2002). Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol 109: S461-478.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Altman LC, Petersen PE, (1988). Successful prevention of an anaphylactoid reaction to iron dextran. Ann Intern Med 109: 346-347.
4. Ansell G, Tweedie MC, West CR, Evans P, Couch L, (1980). The current status of reactions to intravenous contrast media. Invest Radiol 15: S32-S39.
5. Auerbach M, Ballard H, (2010). Clinical use of intravenous iron: administration, efficacy, and safety. Hematology. Am Soc Hematol Educ Program 2010: 338-347.
6. Auerbach M, Chaudhry M, Goldman H, Ballard H, (1998). Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 131: 257-260.
7. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV, (2011). Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 86: 860-862.
8. Bailie GR, (2012). Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm 69: 310-320.
9. Bailie GR, Clark JA, Lane CE, Lane PL, (2005). Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 20: 1443-1449.
10. Bailie GR, Horl WH, Verhoef JJ, (2011). Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Arzneimittelforschung 61: 267-275.
11. Bailie GR, Verhoef JJ, (2012). Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population. Clin Adv Hematol Oncol 10: 101-108.
12. Baller D, Huchzermeyer H, (1989). Histamine effects on the heart with special reference to cardiac side effects of H2 receptor antagonists. Klin Wochenschr 67: 743-755.
13. Banda NK, Mehta G, Chao Y, Wang G, Inturi S, Fossati-Jimack L, et al., (2014). Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. Part Fibre Toxicol 11: 64-74.
14. Baranyi L, Szebeni J, Savay S, Bodo M, Basta M, Bentley TB, et al., (2003). Complement-dependent shock and tissue damage induced by intravenous injection of cholesterol-enriched liposomes in rats. J Applied Res 3: 221-231.
15. Bircher AJ, Auerbach M, (2014). Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 34: 707-723.
16. Black N, (1996). Why we need observational studies to evaluate the effectiveness of health care. BMJ 312: 1215-1218.
17. Brannagan TH, (2002). Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 59: S33-S40.
18. Brennan PJ, Rodriguez BT, Hsu FI, Sloane DE, Castells MC, (2009). Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124: 1259-1266.
19. Brown SG, (2004). Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114: 37-1376.
20. Campbell WD, Lazoura E, et al., (2002). Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46: 131-134.
21. Castells MC, (2008). Hypersensitivity to antineoplastic agents. Curr Pharm Des 14: 2892-2901.
22. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al., (2008). Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122: 574-580.
23. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al., (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 14: 1430-1437.
24. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J, (2004). On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19: 1571-1575.
25. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J, (2006). Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21: 378-382.
26. Coombs RRA, Gell PGH, (1968). Classification of allergic reactions responsible for drug hypersensitivity reactions. In:, Coombs RRA, Gell PGH, (eds). Clinical Aspects of Immunology, 2nd edn. Davis: Philadelphia, PA: pp 575-596.
27. Critchly JU, Dunbar YE, (2007). Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. TATM 9: 8-36.
28. Demoly P, Lebel B, Messaad D, Sahla H, Rongier M, Daures JP, et al., (1999). Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 54: 500-506.
29. Descotes J, Choquet-Kastylevsky G, (2001). Gell and Coombs's classification: is it still valid? Toxicology 158: 3-49.
30. Dézsi L, Fülöp T, Mészáros T, Szénási G, Urbanics R, Vázsonyi C, et al., (2014). Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses. J Contr Release 195: 2-10.
31. Doxil prescribing information, Doxil.com (2014) https://www.doxil.com/shared/product/doxil/prescribing-information.pdf (accessed 10/11/2015).
32. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, et al., (2006). Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 24: 851-858.
33. EMA-CHMP (2013). New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines Vol. EMA/579491/2013, pp 1-3: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/IV-iron-31/WC500151308.pdf (accessed 10/11/2015).
34. Enright T, Chua-Lim A, Duda E, Lim DT, (1989). The role of a documented allergic profile as a risk factor for radiographic contrast media reaction. Ann Allergy 62: 302-305.
35. Fishbane S, (2003). Safety in iron management. Am J Kidney Dis 41: 18-26.
36. Fleming LW, Stewart WK, Parratt D, (1992). Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients. Nephrol Dial Transplant 7: 35-39.
37. Fletes R, Lazarus JM, Gage J, Chertow GM, (2001). Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37: 743-749.
38. Fütterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P, (2013). Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal 86: 151-60.
39. Gabizon AA, Muggia FM, (1998). Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. In:, Woodle MC, Storm G, (eds). Long-Circulating Liposomes: Old Drugs, New Therapeutics, edn. Landes Bioscience: Austin, TX: pp 155-174.
40. Goss JE, Chambers CE, Heupler FA Jr, (1995). Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn 34: 99-104.
41. Hickman MA, Bern stein IL, Palascak JE, (2000). Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Ann Allergy Asthma Immunol 84: 262-263.
42. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC, (2012). Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol 8: 43-52.
43. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al., (2004). Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113: 832-836.
44. Kelsall J, Rogers P, Galindo G, De Vera MA, (2012). Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol 39: 1539-1545.
45. Kemp SF, Lockey RF, Simons FE, (2008). Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy 63: 1061-1070.
46. Keshavarzian A, Mayer L, Salzberg B, Garone M, Finkelstein W, Cappa J, et al., (2007). A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol(NY) 3: 381-390.
47. Lalli AF, (1974). Urographic contrast media reactions and anxiety. Radiology 112: 267-271.
48. Laman CA, Silverstein SB, Rodgers GM, (2005). Parenteral iron therapy: a single institution's experience over a 5-year period. J Natl Compr Canc Netw 3: 791-795.
49. Lazarou J, Pomeranz BH, Corey PN, (1998). Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 279: 1200-1205.
50. Lequerre T, Vittecoq O, Klemmer N, Goeb V, Pouplin S, Menard JF, et al., (2006). Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33: 1307-1314.
51. Lorenz W, Doenicke A, (1985). H1 and H2 blockade: a prophylactic principle in anesthesia and surgery against histamine-release responses of any degree of severity: Part 1. N Engl Reg Allergy Proc 6: 37-57.
52. Mayer L, Young Y, (2006). Infusion reactions and their management. Gastroenterol Clin North Am 35: 857-866.
53. Merkel OM, Urbanics R, Bedöcs P, Rozsnyay Z, Rosivall L, Toth M, et al., (2011). In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-grafted-poly (ethylene glycol) block copolymers. Biomaterials 32: 4936-4942.
54. Misbah SA, Chapel HM, (1993). Adverse effects of intravenous immunoglobulin. Drug Saf 9: 254-262.
55. Monaghan MS, Glasco G, St John G, Bradsher RW, Olsen KM, (1994). Safe administration of iron dextran to a patient who reacted to the test dose. South Med J 87: 1010-2.
56. Nauta AJ, Engels F, Knippels LM, Garssen J, Nijkamp FP, Redegeld FA, (2008). Mechanisms of allergy and asthma. Eur J Pharmacol 585: 354-360.
57. Novey HS, Pahl M, Haydik I, Vaziri ND, (1994). Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 72: 224-228.
58. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42: D1098-1106.
59. Pichler WJ, (2006). Adverse side-effects to biological agents. Allergy 61: 912-920.
60. Puchner TC, Kugathasan S, Kelly KJ, Binion DG, (2001). Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 7: 34-37.
61. Rajan TV, (2003). The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends in Immunol 24: 376-379.
62. Rampton G, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al., (2014). Hypersensitivity reactions to intravenous iron: guidance for risk minimisation and management. Haematologica 99: 1671-1676.
63. Ranft A, Kochs EF, (2004). Treatment of anaphylactic reactions: a review of guidelines and recommendations. AnasthesiolIntensivmedNotfallmed Schmerzther 39: 2-9.
64. Ring J, Grosber M, Mohrenschlager M, Brockow K, (2010). Anaphylaxis: acute treatment and management. Chem Immunol Allergy 95: 201-10. doi: 10.1159/000315953 Epub;%2010 Jun 1.: 201-210.
65. Ring J, Messmer K, (1977). Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1: 466-469.
66. Scott S, Thompson J, (2014). Adverse drug reactions. Anest Intens Care Med 15: 245-249.
67. Shehadi WH, (1982). Contrast media adverse reactions: occurrence, recurrence, and distribution patterns. Radiology 143: 11-17.
68. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al., (2011). World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 4: 13-37.
69. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, et al., (2001). Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 1: 721-735.
70. Szebeni J, (2005). Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 216: 106-121.
71. Szebeni J, (2012). Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanomed 5: 33-53.
72. Szebeni J, (2014). Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 61: 163-173.
73. Szebeni J, Alving CR, Rosivall L, Bünger R, Baranyi L, Bedöcs P, et al., (2007). Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 17: 107-117.
74. Szebeni J, Baranyi L, Sávay S, Bodõ M, Milosevits J, Alving CR, et al., (2006). Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol 290: H1050-1058.
75. Szebeni J, Baranyi L, Savay S, Bodo M, Morse DS, Basta M, et al., (2000). Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol 279: H1319-H1328.
76. Szebeni J, Bedöcs P, Csukás D, Rosivall L, Bunger R, Urbanics R, (2012a). A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 64: 1706-1716.
77. Szebeni J, Bedöcs P, Rozsnyay Z, Weiszhár Z, Urbanics R, Rosivall L, et al., (2012b). Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine NBM 8: 176-184.
78. Szebeni J, Bedöcs P, Urbanics R, Bunger R, Rosivall L, Tõth M, et al., (2012c). Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Contr Rel 160: 382-387.
79. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, et al., (1999). Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99: 2302-2309.
80. Szebeni J, Muggia F, Gabizon A, Barenholz Y, (2011). Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63: 1020-1030.
81. Szebeni J, Wassef NM, Spielberg H, Rudolph AS, Alving CR, (1994). Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Comm 205: 255-263.
82. Tramer MR, von Elm E, Loubeyre P, Hauser C, (2006). Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 333: 675.
83. van der Kolk LE, Grillo-Lõpez AJ, Baars JW, Hack CE, van Oers MH, (2001). Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115: 807-811.
84. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC, (2004). Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 31: 1912-1917.
85. Working Group of the Resuscitation Committee (2013). Emergency treatment of anaphylactic reactions-guideline for health care providers. Resuscitation Council (UK) http://www.resus.org.uk/pages/reaction.pdf (accessed 10/11/2015).
86. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C, (2010). Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 85: 650-654.